Baidu
map

重磅:国务院新规,这五个方面跟你有重大关系!

2017-02-13 大 泽整理 华医网

《意见》是涵盖整个医药产业链的重要改革文件,对医药行业及公立医院未来的发展将产生深远影响。小编特意给大家划了重点,大家一起来学习。全面推行“两票制”综合医改试点省(区、市)和公立医院改革试点城市要率先推行“两票制”,鼓励其他地区实行“两票制”,争取到2018年在全国推开。药品流通企业、医疗机构购销药品要建立信息完备的购销记录,做到票据、账目、货物、货款相一致,随货同行单与药品同行。企业销售药品应按

《意见》是涵盖整个医药产业链的重要改革文件,对医药行业及公立医院未来的发展将产生深远影响。小编特意给大家划了重点,大家一起来学习。

全面推行“两票制”

综合医改试点省(区、市)和公立医院改革试点城市要率先推行“两票制”,鼓励其他地区实行“两票制”,争取到2018年在全国推开。药品流通企业、医疗机构购销药品要建立信息完备的购销记录,做到票据、账目、货物、货款相一致,随货同行单与药品同行。企业销售药品应按规定开具发票和销售凭证。积极推行药品购销票据管理规范化、电子化。

编者按:药品购销两票制是指药品从药厂卖到一级经销商开一次发票,经销商卖到医院再开一次发票,以“两票”替代目前常见的七票、八票,减少流通环节的层层盘剥,并且每个品种的一级经销商不得超过2个。

优先使用基本药物

优化调整基本药物目录。公立医院要全面配备、优先使用基本药物。扩大临床路径覆盖面,2020年底前实现二级以上医院全面开展临床路径管理。医疗机构要将药品采购使用情况作为院务公开的重要内容,每季度公开药品价格、用量、药占比等信息;落实处方点评、中医药辨证施治等规定,重点监控抗生素、辅助性药品、营养性药品的使用,对不合理用药的处方医生进行公示,并建立约谈制度。严格对临时采购药品行为的管理。卫生计生部门要对医疗机构药物合理使用情况进行考核排名,考核结果与院长评聘、绩效工资核定等挂钩。

编者按:新一轮医改启动以来,基本药物制度初步建立,降低了药品价格,群众用药负担有所减轻。但是基本药物种类少、廉价基本药物经常短缺、部分药品质量不高等问题也一直存在,这些问题尽快解决才能让医生放心开基本药物。

鼓励到零售药店购药

坚持医疗、医保、医药联动,统筹推进取消药品加成、调整医疗服务价格、鼓励到零售药店购药等改革,落实政府投入责任,加快建立公立医院补偿新机制。推进医药分开。医疗机构应按药品通用名开具处方,并主动向患者提供处方。门诊患者可以自主选择在医疗机构或零售药店购药,医疗机构不得限制门诊患者凭处方到零售药店购药。具备条件的可探索将门诊药房从医疗机构剥离。探索医疗机构处方信息、医保结算信息与药品零售消费信息互联互通、实时共享。将医药费用控制情况与公立医院财政补助、评先评优、绩效工资核定、院长评聘等挂钩

编者按:政策刚出,广东省就出现了首家实行医药分开的医院。从2月8日起,广州市妇女儿童医疗中心珠江新城院区将成人门诊药房移出医院,患者在看病后,可在院内缴费或不缴费直接打印处方单,持处方单、诊疗卡(或凭诊疗卡号)就可以在院外的大众医药妇儿中心店或其他药店取药。预计2月底,儿童药房也将全部分离出去。

积极发挥药师作用

落实药师权利和责任,充分发挥药师在合理用药方面的作用。各地在推进医疗服务价格改革时,对药师开展的处方审核与调剂、临床用药指导、规范用药等工作,要结合实际统筹考虑,探索合理补偿途径,并做好与医保等政策的衔接。加强零售药店药师培训,提升药事服务能力和水平。加快药师法立法进程。探索药师多点执业。合理规划配置药学人才资源,强化数字身份管理,加强药师队伍建设。

编者按:药师的主要任务是审核、调剂处方,制定个体化用药方案,提供用药咨询服务,参与临床药学工作。但是目前我国医疗机构内工作的药师主要在医院药房工作,与患者接触机会少、时间短,除在处方药品调配前进行审核,保证患者用药安全外,药师所学专业还未得到全面发挥。有了政策的支持,相信药师的职业前景会更好。

规范医保和控制费用

充分发挥各类医疗保险对医疗服务行为、医药费用的控制和监督制约作用,逐步将医保对医疗机构的监管延伸到对医务人员医疗服务行为的监管。探索建立医保定点医疗机构信用等级管理和黑名单管理制度。及时修订医保药品目录。加强医保基金预算管理,大力推进医保支付方式改革,全面推行以按病种付费为主,按人头付费、按床日付费等多种付费方式相结合的复合型付费方式,合理确定医保支付标准,将药品耗材、检查化验等由医疗机构收入变为成本,促使医疗机构主动规范医疗行为、降低运行成本。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1549034, encodeId=4ce3154903426, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574298, encodeId=0bc415e42986f, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176105, encodeId=be091e61059f, content=希望和实际距离还是很大的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Tue Feb 14 11:57:02 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175964, encodeId=9bed1e5964cf, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Mon Feb 13 18:02:46 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175949, encodeId=a66b1e59499e, content=推进合理用药,避免过度治疗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76802018286, createdName=元元maple, createdTime=Mon Feb 13 15:16:48 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175927, encodeId=e9671e59271b, content=鼓励这一举措!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Feb 13 12:29:33 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175917, encodeId=a6a21e591731, content=浏览一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Feb 13 12:13:20 CST 2017, time=2017-02-13, status=1, ipAttribution=)]
    2017-02-15 xxxx1054
  2. [GetPortalCommentsPageByObjectIdResponse(id=1549034, encodeId=4ce3154903426, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574298, encodeId=0bc415e42986f, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176105, encodeId=be091e61059f, content=希望和实际距离还是很大的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Tue Feb 14 11:57:02 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175964, encodeId=9bed1e5964cf, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Mon Feb 13 18:02:46 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175949, encodeId=a66b1e59499e, content=推进合理用药,避免过度治疗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76802018286, createdName=元元maple, createdTime=Mon Feb 13 15:16:48 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175927, encodeId=e9671e59271b, content=鼓励这一举措!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Feb 13 12:29:33 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175917, encodeId=a6a21e591731, content=浏览一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Feb 13 12:13:20 CST 2017, time=2017-02-13, status=1, ipAttribution=)]
    2017-02-15 xsm923
  3. [GetPortalCommentsPageByObjectIdResponse(id=1549034, encodeId=4ce3154903426, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574298, encodeId=0bc415e42986f, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176105, encodeId=be091e61059f, content=希望和实际距离还是很大的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Tue Feb 14 11:57:02 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175964, encodeId=9bed1e5964cf, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Mon Feb 13 18:02:46 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175949, encodeId=a66b1e59499e, content=推进合理用药,避免过度治疗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76802018286, createdName=元元maple, createdTime=Mon Feb 13 15:16:48 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175927, encodeId=e9671e59271b, content=鼓励这一举措!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Feb 13 12:29:33 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175917, encodeId=a6a21e591731, content=浏览一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Feb 13 12:13:20 CST 2017, time=2017-02-13, status=1, ipAttribution=)]
    2017-02-14 医张生

    希望和实际距离还是很大的。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1549034, encodeId=4ce3154903426, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574298, encodeId=0bc415e42986f, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176105, encodeId=be091e61059f, content=希望和实际距离还是很大的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Tue Feb 14 11:57:02 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175964, encodeId=9bed1e5964cf, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Mon Feb 13 18:02:46 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175949, encodeId=a66b1e59499e, content=推进合理用药,避免过度治疗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76802018286, createdName=元元maple, createdTime=Mon Feb 13 15:16:48 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175927, encodeId=e9671e59271b, content=鼓励这一举措!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Feb 13 12:29:33 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175917, encodeId=a6a21e591731, content=浏览一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Feb 13 12:13:20 CST 2017, time=2017-02-13, status=1, ipAttribution=)]
    2017-02-13 yongyuanaiping

    ?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1549034, encodeId=4ce3154903426, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574298, encodeId=0bc415e42986f, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176105, encodeId=be091e61059f, content=希望和实际距离还是很大的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Tue Feb 14 11:57:02 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175964, encodeId=9bed1e5964cf, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Mon Feb 13 18:02:46 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175949, encodeId=a66b1e59499e, content=推进合理用药,避免过度治疗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76802018286, createdName=元元maple, createdTime=Mon Feb 13 15:16:48 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175927, encodeId=e9671e59271b, content=鼓励这一举措!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Feb 13 12:29:33 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175917, encodeId=a6a21e591731, content=浏览一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Feb 13 12:13:20 CST 2017, time=2017-02-13, status=1, ipAttribution=)]
    2017-02-13 元元maple

    推进合理用药,避免过度治疗!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1549034, encodeId=4ce3154903426, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574298, encodeId=0bc415e42986f, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176105, encodeId=be091e61059f, content=希望和实际距离还是很大的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Tue Feb 14 11:57:02 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175964, encodeId=9bed1e5964cf, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Mon Feb 13 18:02:46 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175949, encodeId=a66b1e59499e, content=推进合理用药,避免过度治疗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76802018286, createdName=元元maple, createdTime=Mon Feb 13 15:16:48 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175927, encodeId=e9671e59271b, content=鼓励这一举措!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Feb 13 12:29:33 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175917, encodeId=a6a21e591731, content=浏览一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Feb 13 12:13:20 CST 2017, time=2017-02-13, status=1, ipAttribution=)]
    2017-02-13 inter158

    鼓励这一举措!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1549034, encodeId=4ce3154903426, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574298, encodeId=0bc415e42986f, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Wed Feb 15 02:41:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176105, encodeId=be091e61059f, content=希望和实际距离还是很大的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Tue Feb 14 11:57:02 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175964, encodeId=9bed1e5964cf, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce8c1961256, createdName=yongyuanaiping, createdTime=Mon Feb 13 18:02:46 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175949, encodeId=a66b1e59499e, content=推进合理用药,避免过度治疗!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76802018286, createdName=元元maple, createdTime=Mon Feb 13 15:16:48 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175927, encodeId=e9671e59271b, content=鼓励这一举措!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Feb 13 12:29:33 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175917, encodeId=a6a21e591731, content=浏览一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Feb 13 12:13:20 CST 2017, time=2017-02-13, status=1, ipAttribution=)]
    2017-02-13 wxl882001

    浏览一下

    0

Baidu
map
Baidu
map
Baidu
map